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Abstract
Background:  Chromosome 22q11 deletion syndrome (22q11DS) causes a developmental
disorder during the embryonic stage, usually because of hemizygous deletions. The clinical pictures
of patients with 22q11DS vary because of polymorphisms: on average, approximately 93% of
affected individuals have a de novo deletion of 22q11, and the rest have inherited the same deletion
from a parent. Methods using multiple genetic markers are thus important for the accurate
detection of these microdeletions.
Methods: We studied 12 babies suspected to carry 22q11DS and 18 age-matched healthy controls
from unrelated Taiwanese families. We determined genomic variance using microarray-based
comparative genomic hybridization (array-CGH), quantitative real-time polymerase chain reaction
(qPCR) and multiplex ligation-dependent probe amplification (MLPA).
Results: Changes in genomic copy number were significantly associated with clinical manifestations
for the classical criteria of 22q11DS using MPLA and qPCR (p < 0.01). An identical deletion was
shown in three affected infants by MLPA. These reduced DNA dosages were also obtained partially
using array-CGH and confirmed by qPCR but with some differences in deletion size.
Conclusion: Both MLPA and qPCR could produce a clearly defined range of deleted genomic
DNA, whereas there must be a deleted genome that is not distinguishable using MLPA. These data
demonstrate that such multiple genetic approaches are necessary for the unambiguous molecular
detection of these types of complicated genomic syndromes.
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Background
Chromosome 22q11 deletion syndrome (22q11DS),
including DiGeorge syndrome, velocardiofacial syn-
drome (VCFS) and conotruncal anomaly face syndrome,
is the most frequent known chromosomal microdeletion
syndrome, with an incidence of 1 in 4000 live births [1].
About 93% of probands have the most common mode,
with a de novo deletion of 22q11; 7% have inherited the
22q11 deletion from a parent [2]. However, multiple phe-
notypic features and associated abnormalities are
observed in patients with 22q11DS [3], and phenotypes
vary between families because of deletion polymorphisms
[4]. In general, congenital heart disease (CHD) is the most
common disorder seen, particularly conotruncal malfor-
mations [5]. Variable developmental problems and schiz-
oid features are also associated with this syndrome [6].
The molecular basis for 22q11DS is still elusive. The syn-
drome is apparently caused by a haploinsufficiency of one
or more genes that lie in the long arm of chromosome 22
[7]. On average, approximately 90% of affected individu-
als have a 3 Mb deletion, and 7% have a smaller deletion
spanning 1.5 Mb [6]. Fluorescence in situ hybridization
(FISH) has proved to be a tool for the detection of 22q11
deletions [8]. However, haploinsufficiency can be con-
firmed by FISH deletions only when using conventional
TUPLE1 or N25 probes, based on assumptions about
common deletion breakpoint regions [9,10]. Methods
with multiple genetic markers in the 22q11 region are
increasingly important for the accurate detection of
genomic microdeletions [11,12]. Therefore, microarray-
based comparative genomic hybridization (array-CGH)
and quantitative real-time PCR (qPCR) have been applied
recently in the determination of DNA dosage for
22q11DS [12,13]. Moreover, multiplex ligation-depend-
ent probe amplification (MLPA) analysis with multiple
probes has been used for analysing chromosome 22q11
in detail [14]. Many molecular analyses have shown that
patients with alterations other than microdeletions in the
22q11 region show features overlapping with 22q11DS
[15,16]. These results suggest that this chromosomal
region is particularly vulnerable to genomic alterations.
Thus, comprehensive molecular evaluation is required to
establish the clinical significance of this region.
In this study, MLPA was used to determine genomic DNA
dosage in chromosome 22q11 of infants suspected to har-
bour 22q11DS [14,16]. The range of chromosomal
hemizygosity was also explored for genomic microdele-
tions using array-CGH or qPCR with TaqMan probes to
determine the genome changes precisely [13,17].
Methods
Participants
Twelve babies suspected to carry 22q11DS (B01 to B12,
five boys and seven girls, mean age 2.5 years) from unre-
lated Taiwanese families were enrolled from the Depart-
ments of Pediatrics in Cathay General Hospital and Taipei
Medical University Hospital. A family history and an out-
line classical medical criteria were taken, including testing
for hypocalcaemia caused by idiopathic hypoparathy-
roidism, evaluation for some special forms of CHD such
as tetralogy of Fallot with pulmonic stenosis and dysmor-
phological features typical of the syndrome (Table 1).
Another 18 age-matched healthy controls (C01 to C18, 12
boys and six girls, mean age 5.4 years) were collected at
Cathay General Hospital. Both patients and the healthy
controls were recruited in accordance with the Helsinki
Declaration, and met all ethics criteria. Informed consent
was obtained from the patients' legal representative before
their enrollment. Genomic DNA was obtained from
peripheral blood samples of all participants using stand-
ard methods [18].
Multiplex ligation-dependent probe amplification
MLPA with SALSA P023 DiGeorge syndrome/VCFS kits
(MRC-Holland, Amsterdam, The Netherlands) using a
specifically designed set of probes to detect deletions was
performed in all subjects according to the manufacturer's
instructions. The ligation products were amplified and
analysed as reported previously, with some modification
[17]. Briefly, data were normalized against two of four
healthy controls (two boys and two girls) in each analysis.
DNA dosages with log2 ratios below -0.515 were regarded
as showing haploinsufficiency [19].
Array CGH
Aliquots of 50 ng of genomic DNA from the reference nor-
mal DNA (Promega, Madison, WI, USA) and experimen-
tal samples were amplified using Repli-G Amplification
kits (Qiagen, Hilden, Germany) according to the sup-
plier's protocols. Amplified DNA was digested using the
restriction endonucleases RsaI and AluI for a minimum of
2 h at 37°C, then verified using DNA 500 chips run on a
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA,
USA). Individual reference and experimental samples
were then purified using QIAQuick PCR clean-up kits
(Qiagen). Labelling reactions were performed with 10 μg
of purified DNA and a Bioprime labelling kit (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's
instructions in a volume of 50 μL with a modified dNTP
pool containing 120 μM each of dATP, dGTP and dCTP;
60  μM dTTP; and 60 μM Cy5-dUTP (for experimental
samples) or Cy3-dUTP (for reference samples; Perk-
inElmer). Labelled targets were cleaned up using Centri-
con YM-30 columns (Millipore, Madison, WI, USA).
Experimental and reference targets for each hybridization
were pooled and mixed in a 500 μL hybridization mixture
of 50 μg of human Cot-1 DNA (Invitrogen)/100 μg of
yeast tRNA (Invitrogen)/1 × hybridization control target
DNA (Agilent Technologies)/1 × hybridization buffer
(Agilent Technologies). Before hybridization to the array,BMC Medical Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2350/10/16
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the hybridization mixtures were denatured at 95°C for 3
min and incubated at 37°C for 30 min. To remove any
precipitate, the mixture was centrifuged at ≥ 14,000 g for
5 min, and the supernatant was transferred to a new tube.
The labelled and denatured DNA target was then hybrid-
ized to a human genome CGH 44A microarray (Agilent
Technologies) at 65°C for 40 h. The arrays were then
washed in 0.5 × SSC/0.005% Triton X-102 (wash 1) at
room temperature for 5 min, followed by 5 min at 37°C
in 0.1 × SSC/0.005% Triton X-102 (wash 2). Slides were
dried and scanned using an Agilent DNA microarray scan-
ner at 535 nm for Cy3 and at 625 nm for Cy5. Scanned
images were analysed using Feature Extraction 8.1 soft-
ware, and data analysis was performed using CGH Analyt-
ics software version 3.2 with a moving average of 2 Mb at
a z-score threshold of 2.0 (Agilent Technologies).
Quantitative real-time PCR
Quantitative real-time PCR was used to quantify the DNA
dosage levels for eight probes (BID-2, CO3M, A3M, HIRA-
2, M3M, LZTR1-2, T3M and TO3M) in chromosome
22q11 using a LightCycler thermal cycler system, a Taq-
Man Master kit and a specific probe from the Human Uni-
versal Probe Library according to the manufacturer's
instructions (Table 2; Roche Diagnostics GmbH, Man-
nheim, Germany). Each 20 μL reaction contained 50 ng of
template DNA and was normalized against a reference
endogenous gene (GAPDH, AY340484). Samples retain-
ing both 22q11 alleles were expected to have log2 ratios of
gene dosage close to zero and log2 ratios close to -1 were
regarded as indicating low DNA dosage [12,17,20].
Statistical analysis
Statistical analysis was carried out using SPSS version 13.0
for Windows (SPSS, Chicago, IL, USA). Fisher's exact test
was used to assess the significance of any association
between changes in DNA dosage, and the diagnosis of
22q11DS. P < 0.05 was considered statistically significant.
Results
Distribution of multiple probes on chromosome 22q11
The nine MLPA probes hybridize to a 5.7 Mb genomic
region on chromosome 22q11, and the eight qPCR
probes link to a 3.6 Mb genomic region. Using MLPA, the
most commonly deleted region for 22q11DS started at
probe HIRA-1 downstream of LCR22-A and ended at
probe LZTR1-1 upstream of LCR22-D (Figure 1). The
genomic distance between probes HIRA-1 and LZTR1-1 is
reduced to 1.70 Mb. Similarly, LCR22-A and LCR22-D
flank five probes, A3M to T3M, which are designed in the
most deleted region of 22q11DS for the qPCR method.
Compared with the MLPA probes, both A3M and T3M are
closer to LCR22-A and to LCR22-D (Figure 1).
Determination of genomic deletions on multiple 
chromosomes
MLPA analysis was carried out on blood samples, and pro-
files of DNA dosages are shown in Figure 2. As shown in
Table 1: Clinical characterization of twelve patients suspected to carry 22q11DS
Study subject Age* at last evaluation Gender† Heart defect‡ Dysmorphological facial features Idiopathic hypocalcaemia Others
B01 11.6 ys F PDA/TR/SVC asymmetric crying face/high arch palate/
bifid uvula
Yes
B02 4.0 ys M PPS asymmetric crying face/short nasal bridge/
flat philtrum/hypertelorism
Yes
B03 2.5 mo M PDA/PPS bilateral bizarre, low-set ears/
micrognathia
nil a, b, c
B04 4.1 ys M nil nil Yes d
B05 1.9 ys F VSD/ASD short nasal bridge/hypertelorism/thin 
upper lip
nil e
B06 1.0 mo F ECD cleft palate nil f
B07 10.4 ys F ASD long, thin nose/cleft palate nil
B08 3.5 mo F VSD asymmetric crying face nil
B09 7.5 mo F nil iris coloboma nil
B10 0.1 mo F TOF/PS nil nil
B11 0.2 mo M nil short nasal bridge/hypertelorism/short 
palpbral fissure/post-rotated and bizarre 
ears/cleft palate
nil a, g, h
B12 1.0 mo M nil asymmetric crying face/high arch palate Yes
*ys = years; mo = months.
† M = male; F = female.
‡ PDA = patent ductus arteriosus; TR = tricuspid regurgitation; SVC = superior vena cava; PPS = peripheral pulmonic stenosis; VSD = ventricular 
septum defect; ASD = atrial septal defect; ECD = endocardial cushion defect; TOF = tetralogy of Fallot; PS = pulmonic stenosis.
a, small penis with hypoplasia of scrotum; b, choanal atresia; c, trocheo-esophageal fistula; d, hypoplastic kidney; e, clinodactyly; f, left hand 
polydactyly; g, bilateral hand simian crease; h, esophageal atresia.BMC Medical Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2350/10/16
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Figure 2a, none of the healthy control subjects showed
haploinsufficiency for any probes (range of log2 ratios, -
0.304 to +0.299). In contrast, loss of DNA dosage was
found in three of the suspected 22q11DS infants (B01,
B02 and B12) on chromosome 22q with an identical dele-
tion (1.70 Mb) from probes HIRA-1 to LZTR1-1 (range of
log2 ratio, -0.690 to +1.059; Figure 2b). The other nine
probands did not show any loss of DNA dosage for any
probes on chromosome 22q, and their log2 ratios of DNA
dosages were all close to zero (range of log2 ratio -0.218 to
+0.595). DNA dosages for all the probes for other chro-
mosomes assayed (4q, 10p and 8p) showed no changes
for the 12 proband infants. However, the changes in
genomic copy number in 22q for subjects B01, B02 and
B12 were significantly associated with the classical diag-
Table 2: A list of primer and TaqMan probe for quantitative real-time PCR
Genomic location* Primer Sequence† Probe number‡
BID-2 F: GTGATCTCGGCTCGCTGTA 10
R: CAGCTACTGGGGAAGGATTG
CO3M F: CAGCATAACCACTGCAGGTC 23
R: TAAGGAATTGGCTCATGCAA
A3M F: GAGCTGCCTACAGCTATCCTG 66
R: CTGTGCACGTCAGCAACAC
HIRA-2 F: CATCAGGAAATGCTCTTGGAG 02
R: GCCGAAGCCTTGAGTTTTAG
M3M F: CTGGCTGCACAGGAGACAT 24
R: GAGGCCTTTCCCTTGTATGC
LZTR1-2 F: TCCTGTCAGTTTGCCCTTCT 23
R: TTGCACCACCTAACACTACCA
T3M F: GGTCTGCCCAGAATTAGCAC 10
R: CTGGGTGACTTTCAGCCAAT
TO3M F: CTGGAAAATGGGAAGGAACA 25
R: GCTGCTTCCTCTGCTTGAAA
GAPDH F: GCTGCATTCGCCCTCTTA 10
R: GAGGCTCCTCCAGAATATGTGA
*BID, NM197966; HIRA, X89887; LZTR1, NM006767; GAPDH, AY340484.
† F = forward primer; R = reverse primer.
‡ Probe number, from the Human Universal Probe Library of Roche Diagnostics GmbH, Mannheim, Germany.
Relative position of probes and LCR22s on the chromosome  22q11 region Figure 1
Relative position of probes and LCR22s on the chro-
mosome 22q11 region. MLPA probes (blue bars) are 
arranged according to the manufacturer's instructions (MRC-
Holland). qPCR probes (green bars) are designed for each 
amplicon within and flanking the deletion region. Sequence 
information for probes CO3M, A3M, M3M, T3M and TO3M, 
are derived from Chen et al. [20]. Commonly used FISH 
probes for N25 (a orange fish) TUPLE1 (a brown fish) are 
indicated. Ranges of LCR22-A, -B, -C, and -D, as defined by 
Shaikh et al. [39], are depicted as thick red lines. BID-1 and -
2, in the genome of BID (NM197966); HIRA-1 and -2, in the 
genome of HIRA (X89887); LZTR1-1 and -2, in the genome 
of LZTR1 (NM006767). Genomic distances between probes 
are proportional to the exact size and size of unit genome is 
0.3 Mb as indicated. The orientation of the sequence is cen-
tromere (Cen) to telomere (Tel).
DNA dosage profiles estimated by MLPA analysis Figure 2
DNA dosage profiles estimated by MLPA analysis. 
Ratios on each DNA dosage are plotted relative to single 
DNA samples isolated from (A) 18 healthy controls and (B) 
12 patients suspected to carry 22q11DS. Nine probes are 
ordered by position on chromosome 22q.BMC Medical Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2350/10/16
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nostic criteria for 22q11DS (P  < 0.01 by Fisher's exact
test). MLPA detected a reduced DNA dosage level from
subject B01 on chromosome 22q11, and this was also
shown by the array-CGH analysis (Figure 3).
The qPCR method clearly defines genomic changes in 
chromosome22q11
To confirm and clearly define genomic deletions in the
proband infants, we applied qPCR using TaqMan probes.
Compared with the 18 healthy controls, DNA dosage lev-
els from the 12 patients varied independently (Figure 4).
Genomic imbalance was detected in four of these babies
(B01, B02, B03 and B12), but no detectable changes were
found in the other eight babies or in the healthy controls.
Changes in genomic copy numbers were also significantly
associated with clinical manifestations (P  < 0.01 by
Fisher's exact test). As with the MLPA technique, subjects
B01, B02 and B12 showed large genomic deletions in
22q11 by qPCR (range of log2 ratios -0.79 to -1.32). How-
ever, the size of the deletion in proband B01 was smaller
than in B02 and B12. As shown in Figure 4b, an additional
haploinsufficiency for probe T3M was detected from
probands B02 and B12 (log2  ratios -1.15 and -0.95,
respectively) but not from subject B01 (log2 ratio +0.22).
This proband carried a 2.38 Mb deletion (from probes
A3M to T3M) whereas subjects B02 and B12 each had a
2.27 Mb deletion (from probes A3M to LZTR1-2). Moreo-
ver, subject B03 showed very low DNA dosage (log2 ratio
-3.06) by qPCR, using probe CO3M.
Discussion
Copy number variations in some specific genomic regions
can lead to genetic disorders [21]. MLPA and qPCR can
now be used separately or together to determine genomic
copy numbers in many human diseases [17,22,23]. As the
clinical features of patients suffering from chromosomal
alterations on 22q11 have proved to be extremely poly-
morphic, different approaches have been applied to deter-
mine the DNA copy number in this chromosomal region
[20,24]. Reduced dosage of genes within 22q11 is
believed to cause the phenotype of 22q11DS [25].
Molecular basis of chromosome 22q11 from patients with 
heart malformations
Deletion of chromosome 22q11 appears to be the second
most common cause of CHD after Down syndrome [26].
Jiang et al. have used several polymorphic microsatellite
markers to determine chromosome 22q11 deletions in
patients with isolated CHD [27]. Therefore, genomic
markers for these deletions have become the molecular
basis for studying heart malformations in patients with
22q11DS. Many studies have compared the FISH
approach using commercially available probe (N25 or
TUPLE1) to other methods with multiple molecular
Variations of DNA dosages on chromosome 22q from two  patients suspected to carry 22q11DS by the array-CGH anal- ysis Figure 3
Variations of DNA dosages on chromosome 22q 
from two patients suspected to carry 22q11DS by the 
array-CGH analysis. Scatter plots delineate the log2 ratios 
of differential signals between probes from experimental 
samples and reference normal DNA. Positive values indicate 
DNA dosages of experimental samples being greater than 
that of reference normal DNA, whereas negative values indi-
cate reduced DNA dosages in experimental samples. The 
blue line is plotted as the moving average of a window con-
taining the probes within 2 MB. Relative positions of BID, 
HIRA, and LZTR1 are indicated with black arrows.
DNA dosage profiles determined by quantitative real-time  PCR Figure 4
DNA dosage profiles determined by quantitative 
real-time PCR. Histograms of relative DNA dosage for (A) 
18 healthy controls and (B) 12 patients suspected to carry 
22q11DS. Ratios on each DNA dosage are plotted and nor-
malized with a reference endogenous gene, GAPDH 
(AY340484). Eight probes are ordered by position on chro-
mosome 22q. Samples retaining both alleles, log2 ratio close 
to 0; samples with deleted one allele, log2 ratio close to -1.BMC Medical Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2350/10/16
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probes [20,28]. However, the FISH probe detected the typ-
ically deleted region around the gene for Histone cell cycle
regulation defective, S. cerevisiae, homolog A (HIRA;
X89887) (Figure 1) [10]. Atypical deletions and deletion
polymorphisms won't be detected by this conventional
approach [29-32]. In this study, we used three approaches
– MLPA, array-CGH and qPCR – with multiple molecular
markers to detect genomic copy numbers in chromosome
22q11 for these 12 babies with CHD, idiopathic hypocal-
caemia, or dysmorphological facial features. MLPA has
been used frequently to detect duplications and deletions
in 22q11 [16,28,33,34], and qPCR with universal Taq-
Man probes was first specifically used in the determina-
tion of DNA dosage for subjects with 22q11DS. We found
that both MLPA and qPCR were rapid, reliable, cost-effec-
tive, high-throughput methods for diagnosing 22q11DS
with statistical significance. In our analysis, MLPA and
qPCR produced almost the same measure of haploinsuffi-
ciency for chromosome 22q11 of three of the probands
(B01, B02 and B12) using probes LCR22-A to LCR22-D,
as reported by others using different methods [12,20].
Different chromosomal deletions on chromosome 22q11 
from patients
We confirmed the presence of the 3 Mb common deletion
that accounts for 90% of patients with 22q11DS [6].
Probands B01, B02 and B12 had the same degree of DNA
deletion between probes HIRA-1 and LZTR1-1 using the
MLPA method. Nevertheless, the fragment size detected
by qPCR (2.38 Mb or 2.27 Mb) was larger than that
detected by MLPA (1.70 Mb). This difference resulted
from the different distributions of probes in these two
methods. Briefly, all three of these subjects showed
genomic deletions starting from probe A3M, which
hybridizes about 0.36 Mb upstream from probe HIRA-1
on 22q. In addition, both B02 and B12 showed haploin-
sufficiency that extended to probe T3M, which binds
downstream of probe LZTR1-1. The deleted genome of
probands B02 and B012 on chromosome 22q11 is at least
about 105 Kb longer than when measured using MLPA.
This deleted region detected specifically by qPCR contains
at least four known genes, including SLC7A4
(NW927495), which are associated with VCFS when
deleted [35].
Complex genomic conditions in patients with 22q11DS or 
in suspected cases
Clinically, two of the three haploinsufficient probands
were diagnosed with CHD (B01 with patent ductus arteri-
osus and B02 with peripheral pulmonic stenosis). Five of
the other babies with CHD, including ventricular septum
defect, atrial septal defect, endocardial cushion defect,
tetralogy of Fallot, and pulmonic stenosis, did not show
any genomic deletions within the region of LCR22-A to -
D using MLPA or qPCR. Considering these results along
with previous reports, we agree that two or more types of
deletions are close in size and position within the 3 Mb
common deletion [20]. We also noted that two of the
proband infants with atrial septal defect were without
detectable deletions in this region, as reported by others
[27]. However, one (B03) presented very low DNA dosage
measured by qPCR using the CO3M probe from two inde-
pendent analyses. The male baby was born with gesta-
tional age 34 weeks, birth body weight 1886 gm, body
length 47 cm, and head circumference 29 cm via Cesarean
section. He has no family history of chromosomal anom-
aly, but presents with the clinical manifestations of trian-
gle face, bilateral malformation of ears without external
meatus, markedly low-set ears, micrognathia, small penis
with hypoplasia of scrotum, and choanal atresia (Table
1). There still have many works to evaluate if any single
nucleotide polymorphism or mutation exist within the
region of CO3M and to correlate this bias of DNA dosage
with the clinical manifestations of subject B03. However,
we speculate that such complex genomic conditions
might be common in patients with 22q11DS or in sus-
pected cases.
MLPA and qPCR overmatch the complex, expensive and 
time-consuming methods for detecting genomic 
microdeletions
CGH has been used to screen for multiple chromosomal
aberrations, and it is now frequently united with microar-
ray hybridization for assessing the level of any chromo-
somal imbalance [36,37]. Based on phenotypes
resembling that of 22q11DS, two suspected patients were
examined with array-CGH for whole genome defects
[4,38]. However, no chromosomal imbalance was
detected, with the exception of chromosome 22q. This
result agreed with that obtained by MLPA to some degree,
because only the probes on chromosome 22q represent
genomic deletions whereas probes on chromosomes 4q,
10p and 8p indicate normal copy numbers. On the other
hand, the implementation of qPCR detection in clinical
laboratories will address the need to replace complex,
expensive and time-consuming methods for detecting
genomic microdeletions or duplications of clinical impor-
tance [12].
Conclusion
In conclusion, both MLPA and qPCR produced clearly
defined ranges of deleted genomic DNA. These two
molecular diagnostic methods are quick, easily manipu-
lated and complementary. For the purpose of molecular
diagnosis without any aberration, multiple molecular
approaches are necessary for a complicated genomic syn-
drome such as 22q11DS. Further studies on the compre-
hensive genomic profiling of subjects with 22q11DS will
help the symptomatic treatment and prenatal diagnosis of
fetuses with affected siblings.BMC Medical Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2350/10/16
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